RxDoctor Payments Data

Laura Newman

Nurse Practitioner · Warsaw, INNPI 1265947584

Payments from drug & device makers

$764in general payments, 2019–2025

Across 45 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$190
  • AbbVie$137
  • Dexcom, Inc.$66
  • Abbott$64
  • Boehringer Ingelheim$58
  • Insulet Corporation$42
  • plus $207 from 10 others

What the payments were for

  • Food & beverage$764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$764 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$32,053
Medicare patients
154
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$94,085
JardianceEmpagliflozin56$58,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$31,209
RybelsusSemaglutide14$26,516
FarxigaDapagliflozin Propanediol28$20,059
JanuviaSitagliptin Phosphate19$18,708
MounjaroTirzepatide17$18,011
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$12,841
Breo ElliptaFluticasone/Vilanterol18$12,238
TrintellixVortioxetine Hydrobromide11$6,711
MyrbetriqMirabegron12$5,547
Levemir FlexpenInsulin Detemir23$4,244
Atorvastatin Calcium290$2,244
Albuterol Sulfate HfaAlbuterol Sulfate107$2,139
Celecoxib63$1,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$190$120,60184 claims
Boehringer IngelheimJardiance$58$58,41956 claims
GSKTrelegy Ellipta, Breo Ellipta$15$43,44758 claims
Lilly USA, LLCMounjaro$17$18,01117 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$6,71111 claims
AbbVieSynthroid$137$59411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →